A citation-based method for searching scientific literature

Stergios A Polyzos, Jannis Kountouras, Christos S Mantzoros. Metabolism 2019
Times Cited: 243







List of co-cited articles
538 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.
Zobair M Younossi, Aaron B Koenig, Dinan Abdelatif, Yousef Fazel, Linda Henry, Mark Wymer. Hepatology 2016
25

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.
Naga Chalasani, Zobair Younossi, Joel E Lavine, Michael Charlton, Kenneth Cusi, Mary Rinella, Stephen A Harrison, Elizabeth M Brunt, Arun J Sanyal. Hepatology 2018
17

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.
Zobair Younossi, Quentin M Anstee, Milena Marietti, Timothy Hardy, Linda Henry, Mohammed Eslam, Jacob George, Elisabetta Bugianesi. Nat Rev Gastroenterol Hepatol 2018
14

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.
Eduardo Vilar-Gomez, Yadina Martinez-Perez, Luis Calzadilla-Bertot, Ana Torres-Gonzalez, Bienvenido Gra-Oramas, Licet Gonzalez-Fabian, Scott L Friedman, Moises Diago, Manuel Romero-Gomez. Gastroenterology 2015
894
13



Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
Matthew James Armstrong, Piers Gaunt, Guruprasad P Aithal, Darren Barton, Diana Hull, Richard Parker, Jonathan M Hazlehurst, Kathy Guo, George Abouda, Mark A Aldersley,[...]. Lancet 2016
838
11

Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease.
Kerry L Donnelly, Coleman I Smith, Sarah J Schwarzenberg, Jose Jessurun, Mark D Boldt, Elizabeth J Parks. J Clin Invest 2005
11

Treatment of NAFLD with diet, physical activity and exercise.
Manuel Romero-Gómez, Shira Zelber-Sagi, Michael Trenell. J Hepatol 2017
434
9

Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis.
Simona Leoni, Francesco Tovoli, Lucia Napoli, Ilaria Serio, Silvia Ferri, Luigi Bolondi. World J Gastroenterol 2018
175
8

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Arun J Sanyal, Naga Chalasani, Kris V Kowdley, Arthur McCullough, Anna Mae Diehl, Nathan M Bass, Brent A Neuschwander-Tetri, Joel E Lavine, James Tonascia, Aynur Unalp,[...]. N Engl J Med 2010
8

The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis.
Zobair M Younossi, Pegah Golabi, Leyla de Avila, James Minhui Paik, Manirath Srishord, Natsu Fukui, Ying Qiu, Leah Burns, Arian Afendy, Fatema Nader. J Hepatol 2019
451
8

Mechanisms of NAFLD development and therapeutic strategies.
Scott L Friedman, Brent A Neuschwander-Tetri, Mary Rinella, Arun J Sanyal. Nat Med 2018
8


Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial).
Mohammad Shafi Kuchay, Sonal Krishan, Sunil Kumar Mishra, Khalid Jamal Farooqui, Manish Kumar Singh, Jasjeet Singh Wasir, Beena Bansal, Parjeet Kaur, Ganesh Jevalikar, Harmendeep Kaur Gill,[...]. Diabetes Care 2018
228
7

The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD).
Elena Buzzetti, Massimo Pinzani, Emmanuel A Tsochatzis. Metabolism 2016
7

Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.
Chris Estes, Homie Razavi, Rohit Loomba, Zobair Younossi, Arun J Sanyal. Hepatology 2018
725
7

Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Masanori Shimizu, Kunihiro Suzuki, Kanako Kato, Teruo Jojima, Toshie Iijima, Toshimitsu Murohisa, Makoto Iijima, Hidehiro Takekawa, Isao Usui, Hideyuki Hiraishi,[...]. Diabetes Obes Metab 2019
129
6

Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial.
Daisuke Ito, Satoshi Shimizu, Kazuyuki Inoue, Daigo Saito, Morifumi Yanagisawa, Kouichi Inukai, Yuji Akiyama, Yoshihiro Morimoto, Mitsuhiko Noda, Akira Shimada. Diabetes Care 2017
148
6

Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
Kenneth Cusi, Beverly Orsak, Fernando Bril, Romina Lomonaco, Joan Hecht, Carolina Ortiz-Lopez, Fermin Tio, Jean Hardies, Celia Darland, Nicolas Musi,[...]. Ann Intern Med 2016
452
6

Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies.
Norbert Stefan, Hans-Ulrich Häring, Kenneth Cusi. Lancet Diabetes Endocrinol 2019
293
6

Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.
Laurent Castera, Mireen Friedrich-Rust, Rohit Loomba. Gastroenterology 2019
418
6

Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease.
David Højland Ipsen, Jens Lykkesfeldt, Pernille Tveden-Nyborg. Cell Mol Life Sci 2018
320
6

Adipose tissue, obesity and non-alcoholic fatty liver disease.
Stergios A Polyzos, Jannis Kountouras, Christos S Mantzoros. Minerva Endocrinol 2017
81
7

MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease.
Mohammed Eslam, Arun J Sanyal, Jacob George. Gastroenterology 2020
667
6

Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations.
Sandra Milić, Davorka Lulić, Davor Štimac. World J Gastroenterol 2014
222
6

Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.
D R Matthews, J P Hosker, A S Rudenski, B A Naylor, D F Treacher, R C Turner. Diabetologia 1985
6

Bariatric surgery improves nonalcoholic fatty liver disease: a contemporary systematic review and meta-analysis.
Tannous K Fakhry, Rahul Mhaskar, Theresa Schwitalla, Elnara Muradova, John Paul Gonzalvo, Michel M Murr. Surg Obes Relat Dis 2019
64
7

Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial.
Sabine Kahl, Sofiya Gancheva, Klaus Straßburger, Christian Herder, Jürgen Machann, Hisayuki Katsuyama, Stefan Kabisch, Elena Henkel, Stefan Kopf, Merit Lagerpusch,[...]. Diabetes Care 2020
73
6

Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.
Stuart McPherson, Tim Hardy, Elsbeth Henderson, Alastair D Burt, Christopher P Day, Quentin M Anstee. J Hepatol 2015
570
5

Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study.
Jan W Eriksson, Per Lundkvist, Per-Anders Jansson, Lars Johansson, Mats Kvarnström, Linda Moris, Tasso Miliotis, Gun-Britt Forsberg, Ulf Risérus, Lars Lind,[...]. Diabetologia 2018
148
5

The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
Vasilios G Athyros, Theodore K Alexandrides, Helen Bilianou, Evangelos Cholongitas, Michael Doumas, Emmanuel S Ganotakis, John Goudevenos, Moses S Elisaf, Georgios Germanidis, Olga Giouleme,[...]. Metabolism 2017
153
5

NAFLD: a multisystem disease.
Christopher D Byrne, Giovanni Targher. J Hepatol 2015
5

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
Renata Belfort, Stephen A Harrison, Kenneth Brown, Celia Darland, Joan Finch, Jean Hardies, Bogdan Balas, Amalia Gastaldelli, Fermin Tio, Joseph Pulcini,[...]. N Engl J Med 2006
5

Obesity: global epidemiology and pathogenesis.
Matthias Blüher. Nat Rev Endocrinol 2019
917
5

Obesity alters gut microbial ecology.
Ruth E Ley, Fredrik Bäckhed, Peter Turnbaugh, Catherine A Lozupone, Robin D Knight, Jeffrey I Gordon. Proc Natl Acad Sci U S A 2005
5

Metabolic endotoxemia initiates obesity and insulin resistance.
Patrice D Cani, Jacques Amar, Miguel Angel Iglesias, Marjorie Poggi, Claude Knauf, Delphine Bastelica, Audrey M Neyrinck, Francesca Fava, Kieran M Tuohy, Chantal Chabo,[...]. Diabetes 2007
5

Complications, morbidity and mortality of nonalcoholic fatty liver disease.
Alessandro Mantovani, Eleonora Scorletti, Antonella Mosca, Anna Alisi, Christopher D Byrne, Giovanni Targher. Metabolism 2020
106
5

Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis.
Stergios A Polyzos, Eun Seok Kang, Chrysoula Boutari, Eun-Jung Rhee, Christos S Mantzoros. Metabolism 2020
44
11

Adipokines in nonalcoholic fatty liver disease.
Stergios A Polyzos, Jannis Kountouras, Christos S Mantzoros. Metabolism 2016
158
5

A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.
Mohammed Eslam, Philip N Newsome, Shiv K Sarin, Quentin M Anstee, Giovanni Targher, Manuel Romero-Gomez, Shira Zelber-Sagi, Vincent Wai-Sun Wong, Jean-François Dufour, Jörn M Schattenberg,[...]. J Hepatol 2020
715
5

Nonobese Fatty Liver Disease.
Donghee Kim, W Ray Kim. Clin Gastroenterol Hepatol 2017
177
5

Design and validation of a histological scoring system for nonalcoholic fatty liver disease.
David E Kleiner, Elizabeth M Brunt, Mark Van Natta, Cynthia Behling, Melissa J Contos, Oscar W Cummings, Linda D Ferrell, Yao-Chang Liu, Michael S Torbenson, Aynur Unalp-Arida,[...]. Hepatology 2005
5

Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.
Chris Estes, Quentin M Anstee, Maria Teresa Arias-Loste, Heike Bantel, Stefano Bellentani, Joan Caballeria, Massimo Colombo, Antonio Craxi, Javier Crespo, Christopher P Day,[...]. J Hepatol 2018
482
5

Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
Peter J Eddowes, Magali Sasso, Michael Allison, Emmanouil Tsochatzis, Quentin M Anstee, David Sheridan, Indra N Guha, Jeremy F Cobbold, Jonathan J Deeks, Valérie Paradis,[...]. Gastroenterology 2019
316
5

Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.
Qing Ye, Biyao Zou, Yee Hui Yeo, Jie Li, Daniel Q Huang, Yuankai Wu, Hongli Yang, Chuanli Liu, Leslie Y Kam, Xiang Xuan Eunice Tan,[...]. Lancet Gastroenterol Hepatol 2020
144
5

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
Philip N Newsome, Kristine Buchholtz, Kenneth Cusi, Martin Linder, Takeshi Okanoue, Vlad Ratziu, Arun J Sanyal, Anne-Sophie Sejling, Stephen A Harrison. N Engl J Med 2021
217
5

Hepatic histology in obese patients undergoing bariatric surgery.
Mariana Machado, Pedro Marques-Vidal, Helena Cortez-Pinto. J Hepatol 2006
345
4

A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease.
Shira Zelber-Sagi, Ada Kessler, Eli Brazowsky, Muriel Webb, Yoav Lurie, Moshe Santo, Moshe Leshno, Laurence Blendis, Zamir Halpern, Ran Oren. Clin Gastroenterol Hepatol 2006
212
4

Association of Weight Loss Interventions With Changes in Biomarkers of Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis.
Dimitrios A Koutoukidis, Nerys M Astbury, Kate E Tudor, Elizabeth Morris, John A Henry, Michaela Noreik, Susan A Jebb, Paul Aveyard. JAMA Intern Med 2019
84
4


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.